Pressure BioSciences Expands on Recent Achievement of Major Development Milestones in Ultra Shear Technology for Diverse High Value Products, Including CBD Oil

Interviewing with Proactive Investors, CEO Richard T. Schumacher Also Highlights and Accentuates Importance of Timely Appointment of Dr. Brad Young as Chief Commercial Officer

SOUTH EASTON, MA / ACCESSWIRE / November 28, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that Richard T. Schumacher, President and CEO, was interviewed by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London.

Ultra Shear Technology ("UST"), the Company's proprietary processing method, uniquely combines ultra high pressure with intense shearing forces to potentially create a wide range of high value product innovations for multiple major consumer and industrial markets. During the interview, Mr. Schumacher discussed the two major milestones recently achieved by the Company in its accelerated UST development program. While doing so, he described how the Company recently completed the development of the first working prototype of the UST system and had subsequently used this prototype system to demonstrate a unique and profound capability for making high value oil-based materials dissolve in water. Mr. Schumacher expanded on the Company's vision for applying this ability to make oils soluble in water, which he believed would allow the Company to enter or serve multiple large and growing markets, including food and beverages, pharmaceuticals, nutraceuticals, and cosmetics.

Responding to Ms. Corrado's questions, Mr. Schumacher stated that the Company had selected an initial focus for these efforts on the rapidly-growing CBD Oil market, estimated by the Brightfield Group to grow to about $22 billion by 2022. Mr. Schumacher pointed out that water soluble CBD could potentially solve several critical issues currently throttling development of this market, including the need to significantly increase the efficiency of CBD absorption by the body, the need to decrease the cost of CBD production per use, and the need to produce high quality, water soluble CBD with minimized quantities of added chemicals. Mr. Schumacher then discussed why he believes PBI's proprietary UST platform could successfully meet these requirements.

Mr. Schumacher also devoted considerable attention to discussing the recent addition of the Company's new Chief Commercial Officer, Dr. Bradford A. Young, including an overview of Dr. Young's blend of scientific and business education and leadership experience. Mr. Schumacher underlined his excitement for the contribution he anticipated from Dr. Young in developing and implementing a new commercialization strategy for the Company that could successfully drive product adoption and accelerate revenue growth. Mr. Schumacher concluded by noting that Dr. Young and he had begun to explore potential opportunities in the CBD space and that they had received strong interest from several groups with whom they had spoken.

Jeffrey N. Peterson, PBI's Board Chairman , stated: "We are very pleased to have had the opportunity to share the Company's recent milestones with a rapidly expanding, worldwide audience of potential investors, partners, customers, and collaborators. Proactive Investors is a well-respected, far-reaching multi-media news organization with the ability to effectively broadcast the corporate stories investors need to hear. We appreciated the insightful interview opportunity with Christine Corrado and we hope that many of their viewers will have the opportunity to watch this milestone interview. Ric Schumacher does an excellent job of explaining the expected impact of our powerful new UST platform, in conveying our excitement for the potential of this proprietary system to be a game-changer in the CBD/cannabinoids and other marketplaces, and in discussing the potential impact that the UST platform could have on our future revenue and growth."

Click here to access the video interview.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President and CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman of the Board (650) 812-8121 (T)

SOURCE: Pressure BioSciences, Inc.

Released November 28, 2018